Page 100 - 《中国药房》2023年9期

vant olaparib for patients with BRCA1- or BRCA2-mu‐ assessments associated with outcome distinctions for adult
tated breast cancer[J]. N Engl J Med，2021，384（25）： and pediatric cancers：loss of BRCA1 in neuroblastoma as‐
2394-2405. sociates with a lower survival probability[J]. Gene，2022，
[ 8 ] ROBSON M，IM S A，SENKUS E，et al. Olaparib for 836：146673.
metastatic breast cancer in patients with a germline BRCA [21] WANG Y，MA B B，LIU X X，et al. ZFP281-BRCA2 pre‐
mutation[J]. N Engl J Med，2017，377（6）：523-533. vents R-loop accumulation during DNA replication[J].
[ 9 ] IM S A，XU B H，LI W，et al. Olaparib monotherapy for Nat Commun，2022，13（1）：3493.
Asian patients with a germline BRCA mutation and [22] EDAILY S，ABDEL-RAZEQ H. Management strategies
HER2-negative metastatic breast cancer：OlympiAD ran‐ of breast cancer patients with BRCA1 and BRCA2 patho‐
domized trial subgroup analysis[J]. Sci Rep，2020，10（1）： genic germline variants[J]. Onco Targets Ther，2022，15：
8753. 815-826.
[10] ROBSON M E，TUNG N，CONTE P，et al. OlympiAD fi‐ [23] YU J，ZHANG C，SHI W，et al. BRCA2 deficiency in‐
nal overall survival and tolerability results：Olaparib ver‐ creases sensitivity of medulloblastoma to Olaparib by in‐
sus chemotherapy treatment of physician’s choice in pa‐ hibiting RAD51-mediated DNA damage repair system[J].
tients with a germline BRCA mutation and HER2-nega‐ Clin Transl Oncol，2022，24（5）：919-926.
tive metastatic breast cancer[J]. Ann Oncol，2019，30（4）： [24] GUPTA T，VINAYAK S，TELLI M. Emerging strategies：
558-566. PARP inhibitors in combination with immune checkpoint
[11] FASCHING P A，LINK T，HAUKE J，et al. Neoadjuvant blockade in BRCA1 and BRCA2 mutation-associated and
paclitaxel/olaparib in comparison to paclitaxel/carboplati‐ triple-negative breast cancer[J]. Breast Cancer Res Treat，
num in patients with HER2-negative breast cancer and ho‐ 2023，197（1）：51-56.
mologous recombination deficiency （GeparOLA study） [25] LUO L J，KEYOMARSI K. PARP inhibitors as single
[J]. Ann Oncol，2021，32（1）：49-57. agents and in combination therapy：the most promising
[12] FELICIO P S，GRASEL R S，CAMPACCI N，et al. treatment strategies in clinical trials for BRCA-mutant
Whole-exome sequencing of non-BRCA1/BRCA2 muta‐ ovarian and triple-negative breast cancers[J]. Expert Opin
tion carrier cases at high-risk for hereditary breast/ovarian Investig Drugs，2022，31（6）：607-631.
cancer[J]. Hum Mutat，2021，42（3）：290-299. [26] WANG Q W，BERGHOLZ J S，DING L Y，et al. STING
[13] LI S，SILVESTRI V，LESLIE G，et al. Cancer risks asso- agonism reprograms tumor-associated macrophages and
ciated with BRCA1 and BRCA2 pathogenic variants[J]. J overcomes resistance to PARP inhibition in BRCA1-defi‐
Clin Oncol，2022，40（14）：1529-1541. cient models of breast cancer[J]. Nat Commun，2022，13
[14] MOMOZAWA Y，SASAI，USUI Y，et al. Expansion of （1）：3022.
cancer risk profile for BRCA1 and BRCA2 pathogenic [27] MENEZES M C S，RAHEEM F，MINA，et al. PARP in‐
variants[J]. JAMA Oncol，2022，8（6）：871-878. hibitors for breast cancer：germline BRCA1/2 and beyond
[15] LEE A，MOON B I，KIM T H. BRCA1/BRCA2 patho‐ [J]. Cancers （Basel），2022，14（17）：4332.
genic variant breast cancer：treatment and prevention stra- [28] LAU C H，SEOW K M，CHEN K H. The molecular
tegies[J]. Ann Lab Med，2020，40（2）：114-121. mechanisms of actions，effects，and clinical implications
[16] FOO T K，XIA B. BRCA1-dependent and independent re‐ of PARP inhibitors in epithelial ovarian cancers：a syste-
cruitment of PALB2-BRCA2-RAD51 in the DNA damage matic review[J]. Int J Mol Sci，2022，23（15）：8125.
response and cancer[J]. Cancer Res，2022，82（18）：3191- [29] WANG Y J，LUO W B，WANG Y F. PARP-1 and its asso‐
3197. ciated nucleases in DNA damage response[J]. DNA Re‐
[17] FU X Y，TAN W，SONG Q B，et al. BRCA1 and breast pair （Amst），2019，81：102651.
cancer：molecular mechanisms and therapeutic strategies [30] WILSON Z，ODEDRA R，WALLEZ Y，et al. ATR inhibi‐
[J]. Front Cell Dev Biol，2022，10：813457. tor AZD6738 （ceralasertib） exerts antitumor activity as a
[18] ZHUANG J J，CHEN P，WU Y H，et al. Brca1 is regu‐ monotherapy and in combination with chemotherapy and
lated by the transcription factor Gata3，and its silencing the PARP inhibitor olaparib[J]. Cancer Res，2022，82（6）：
promotes neural differentiation in retinal neurons[J]. Int J 1140-1152.
Mol Sci，2022，23（22）：13860. [31] KIM D，NAM H J. PARP inhibitors：clinical limitations
[19] CREMONA M，VANDENBERG C J，FARRELLY A M， and recent attempts to overcome them[J]. Int J Mol Sci，
et al. BRCA mutations lead to XIAP overexpression and 2022，23（15）：8412.
sensitise ovarian cancer to inhibitor of apoptosis （IAP） （收稿日期：2023-01-16 修回日期：2023-02-08）
family inhibitors[J]. Br J Cancer，2022，127（3）：488-499. （编辑：舒安琴）
[20] VARKHEDI M，BARKER V R，EAKINS R A，et al. CNV

· 1114 · China Pharmacy 2023 Vol. 34 No. 9 中国药房 2023年第34卷第9期